Tourmaline Bio Stock Performance
| TRML Stock | 16.01 1.49 10.26% |
The entity has a beta of 0.28, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Tourmaline Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tourmaline Bio is expected to be smaller as well. At this point, Tourmaline Bio has a negative expected return of -0.0781%. Please make sure to validate Tourmaline Bio's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Tourmaline Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tourmaline Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent primary indicators, Tourmaline Bio is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 10.26 | Five Day Return 32.1 | Year To Date Return (22.43) | Ten Year Return (90.15) | All Time Return (90.15) |
Last Split Factor 1:10 | Dividend Date 2023-10-20 | Last Split Date 2023-10-20 |
1 | Cantor Fitzgerald Comments on Tourmaline Bio FY2025 Earnings | 01/22/2025 |
2 | Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference | 01/27/2025 |
3 | Acquisition by Kulkarni Sandeep Chidambar of 226000 shares of Tourmaline Bio at 15.54 subject to Rule 16b-3 | 02/03/2025 |
4 | Leerink Partnrs Boosts Earnings Estimates for Tourmaline Bio - MarketBeat | 02/12/2025 |
5 | Tourmaline Bio Earns Outperform Rating from Analysts at Lifesci Capital | 02/27/2025 |
6 | H.C. Wainwright raises Tourmaline Bio stock target to 50 - Investing.com | 03/14/2025 |
7 | Tourmaline Bio Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView | 03/17/2025 |
8 | Pictet Asset Management Holding SA Boosts Holdings in Tourmaline Bio, Inc. | 04/03/2025 |
9 | Is Tourmaline Bio Gaining Ground in the Biotech Sector | 04/16/2025 |
| Begin Period Cash Flow | 141 M |
Tourmaline | Build AI portfolio with Tourmaline Stock |
Tourmaline Bio Relative Risk vs. Return Landscape
If you would invest 1,788 in Tourmaline Bio on January 18, 2025 and sell it today you would lose (187.00) from holding Tourmaline Bio or give up 10.46% of portfolio value over 90 days. Tourmaline Bio is currently does not generate positive expected returns and assumes 4.5451% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Tourmaline, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tourmaline Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tourmaline Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tourmaline Bio, and traders can use it to determine the average amount a Tourmaline Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0172
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRML |
Estimated Market Risk
| 4.55 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tourmaline Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tourmaline Bio by adding Tourmaline Bio to a well-diversified portfolio.
Tourmaline Bio Fundamentals Growth
Tourmaline Stock prices reflect investors' perceptions of the future prospects and financial health of Tourmaline Bio, and Tourmaline Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tourmaline Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 153.16 M | ||||
| Shares Outstanding | 25.69 M | ||||
| Price To Book | 1.37 X | ||||
| EBITDA | (89.73 M) | ||||
| Net Income | (73.21 M) | ||||
| Total Debt | 244 K | ||||
| Book Value Per Share | 11.71 X | ||||
| Cash Flow From Operations | (77.26 M) | ||||
| Earnings Per Share | (2.89) X | ||||
| Market Capitalization | 411.22 M | ||||
| Total Asset | 309 M | ||||
| Retained Earnings | (135.26 M) | ||||
| Working Capital | 259.93 M | ||||
About Tourmaline Bio Performance
By examining Tourmaline Bio's fundamental ratios, stakeholders can obtain critical insights into Tourmaline Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Tourmaline Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.24) | (0.23) |
Things to note about Tourmaline Bio performance evaluation
Checking the ongoing alerts about Tourmaline Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tourmaline Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tourmaline Bio generated a negative expected return over the last 90 days | |
| Tourmaline Bio has high historical volatility and very poor performance | |
| Tourmaline Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (73.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tourmaline Bio generates negative cash flow from operations | |
| Tourmaline Bio has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Is Tourmaline Bio Gaining Ground in the Biotech Sector |
- Analyzing Tourmaline Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tourmaline Bio's stock is overvalued or undervalued compared to its peers.
- Examining Tourmaline Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tourmaline Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tourmaline Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tourmaline Bio's stock. These opinions can provide insight into Tourmaline Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.